Analysts zero in on three Bristol Myers programs as company gears up for multiple data readouts through 2026
read at Endpoints ↗Neutral
Analysts are closely watching Bristol Myers Squibb's pipeline, focusing on three key programs that could drive growth in the coming years.
Wall Street expects a flurry of data readouts, with at least half a dozen trial results slated for release by the end of 2026, intensifying scrutiny on the company's development strategy.
The heightened attention reflects optimism about the potential of these programs, but also underscores the pressure on Bristol Myers to deliver positive outcomes that meet market expectations.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Analysts focus on three programs in big year for Bristol Myers”
read at Endpoints ↗84 words · retrieved Apr 30
comments(0)
5-min edit window · permanent after that